Shire finally gets Baxalta to the deal-talks table

Shire CEO Flemming Ornskov

Shire ($SHPG) is reportedly one step closer to achieving its dream of nabbing Baxalta ($BXLT) to become a global rare-disease leader. The two companies are in takeover talks, Bloomberg reported Friday, with the Illinois pharma looking for a sweetened bid with a cash component. The way Shire sees it, a combined company could generate $20 billion in sales by 2020, with as many as 30 new drugs rolling out over the next 5 years, CEO Flemming Ornskov has said. More from FiercePharma